CanniMed Therapeutics Inc. Reports Financial Results for Q3 2017

CanniMed Therapeutics Inc. (TSX:CMED)today released its financial results for the three and nine months ended July 31, 2017. Highlights Sales of $4.8 million in the quarter were 80 per cent higher than in the comparable period of the prior year and were 29 per cent higher than the second quarter of 2017.

India Globalization Capital, Inc. (NYSE: IGC) Provides Update on Data Linking THC to Decrease in Aβ40 Protein Production

India Globalization Capital, Inc. (NYSE American: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning announced compelling in vitro data compiled from genetically engineered cell lines showing that, at varying concentrations of THC, the production of Aβ40 protein decreases by as much as 50 percent over a 48-hour period.

Supreme Completes First Sales with Aurora Cannabis

Supreme Pharmaceuticals Inc. (TSXV:FIRE) is pleased to announce its wholly owned subsidiary, 7ACRES, has completed its first sale of dried cannabis to Aurora Cannabis Inc., one of Canada’s leading Licensed Producers.